Papua New Guinea vs Philippines: Antiretroviral therapy coverage for PMTCT
Papua New Guinea
28.0%
in 2024
Philippines
16.0%
in 2024
Papua New Guinea rank
78th
Philippines rank
80th
Antiretroviral therapy coverage for PMTCT over time
- Papua New Guinea
- Philippines
How they compare
Papua New Guinea currently reports 28.0% against 16.0% in Philippines, a difference of 12.0%.
That makes Papua New Guinea's figure about 1.8 times Philippines's.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Philippines ahead.
Papua New Guinea ranks 78th and Philippines ranks 80th of 84 countries.
Across the 3 decades both report, Papua New Guinea averaged higher in 1 and Philippines in 2.
Head to head by decade
| Decade | Papua New Guinea | Philippines | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.7% | 5.0% | 4.3% | Philippines |
| 2010s | 10.9% | 13.5% | 2.6% | Philippines |
| 2020s | 20.6% | 15.4% | 5.2% | Papua New Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage for pmtct, Papua New Guinea or Philippines?
- Papua New Guinea, at 28.0% against 16.0% in Philippines as of 2024.
- What is the difference in antiretroviral therapy coverage for pmtct between Papua New Guinea and Philippines?
- 12.0%, with Papua New Guinea ahead.
- How many years of comparable data are there for Papua New Guinea and Philippines?
- 25 years are reported by both, from 2000 to 2024.
- How do Papua New Guinea and Philippines rank globally for antiretroviral therapy coverage for pmtct?
- Papua New Guinea ranks 78th and Philippines ranks 80th of 84 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).